Why it matters:
A cannabis company in Jamaica has successfully exported cannabis-derived THC products to the United States for testing, marking the first legal export of THC from Jamaica to the US. This move showcases Jamaica’s role in the global cannabis supply chain.
What they are saying:
The CEO of Pure Jamaican and Seven-10 Pharmaceuticals, Scott Cathcart, is proud of this milestone and sees it as a step towards establishing Jamaica as a leader in the global cannabis ecosystem. The President of Jamaica Promotions Corp. (JAMPRO) also commended the success of Pure Jamaican and Seven-10 Pharmaceuticals in exporting medicinal cannabis formulations to Brazil.
The big picture:
This export of cannabis products from Jamaica to the US comes at a time when the DEA is considering rescheduling marijuana under federal law, which could ease restrictions on cannabis research and pharmaceutical approvals. If the DEA approves the rescheduling, Seven-10 intends to ship THC products to US patients with valid prescriptions.
What to watch:
Keep an eye on the DEA’s decision regarding the rescheduling of marijuana, as it could impact the future of cannabis exports and pharmaceutical approvals. Additionally, watch for further developments in Jamaica’s cannabis industry and its role in the global market.
My take:
The successful export of THC products from Jamaica to the US is a significant milestone for both countries and could pave the way for increased cooperation and opportunities in the global cannabis industry. It will be interesting to see how this move influences the future of cannabis research, pharmaceutical approvals, and international trade in the coming years.
